Business Description
Aravive Inc
NAICS : 325412
SIC : 2834
ISIN : US92529L1026
Description
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.39 | |||||
| 9-Day RSI | 17.8 | |||||
| 14-Day RSI | 18.15 | |||||
| 6-1 Month Momentum % | -90.75 | |||||
| 12-1 Month Momentum % | -93.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -848.44 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-Forward-EBIT | -0.07 | |||||
| EV-to-Forward-EBITDA | -0.07 | |||||
| EV-to-Forward-Revenue | 1.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aravive Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.542 | ||
| EPS (TTM) (€) | -0.899 | ||
| Beta | 0 | ||
| Volatility % | 125.64 | ||
| 14-Day RSI | 18.15 | ||
| 14-Day ATR (€) | 0.005662 | ||
| 20-Day SMA (€) | 0.074725 | ||
| 12-1 Month Momentum % | -93.12 | ||
| 52-Week Range (€) | 0.0325 - 2.224 | ||
| Shares Outstanding (Mil) | 73.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aravive Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aravive Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aravive Inc Frequently Asked Questions
What is Aravive Inc(FRA:VE11)'s stock price today?
The current price of FRA:VE11 is €0.03. The 52 week high of FRA:VE11 is €2.22 and 52 week low is €0.03.
When is next earnings date of Aravive Inc(FRA:VE11)?
The next earnings date of Aravive Inc(FRA:VE11) is 2025-03-15 Est..
Does Aravive Inc(FRA:VE11) pay dividends? If so, how much?
Aravive Inc(FRA:VE11) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers